GlassScriptPhysician profile
Goolcher J Wadia
NPI 1215987706
$1,246.48
in general payments reported to CMS, 2019-2025
14 companies · $615 in 2025
The $615 reported for 2025 was more than what 92% of Anesthesiology providers received nationally (typical 2025 total: $58.09).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $12.20 · 2022: $15.13 · 2023: $118 · 2024: $487 · 2025: $615.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,201 · Education: $17.80.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,201.35 |
| Education | $17.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $406.19 | 2024-2025 | |
| Janssen Biotech, INC. | $307.81 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Qol Medical, LLC | $127.09 | 2024-2025 | Sucraid, Sucraid |
| Lilly USA, LLC | $94.36 | 2024-2025 | Omvoh |
| Madrigal Pharmaceuticals | $84.69 | 2024 | Resmetirom |
| Takeda Pharmaceuticals U.S.A., INC. | $51.33 | 2023-2025 | Gattex, Entyvio |
| Merck Sharp & Dohme LLC | $27.33 | 2021-2022 | |
| Alexion Pharmaceuticals, INC. | $27.02 | 2024 | Ultomiris |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $24.15 | 2025 | Xifaxan |
| Regeneron Healthcare Solutions, INC. | $22.68 | 2023 | Dupixent |
| Ardelyx, INC. | $21.04 | 2025 | Ibsrela |
| Boston Scientific Corporation | $20.21 | 2025 | General - Hemostasis |
| Celltrion USA INC. | $17.80 | 2024 | Zymfentra |
| Evoke Pharma, INC. | $14.78 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Goolcher Wadia listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.